From: Diagnosis and Treatment of Urticaria and Angioedema: A Worldwide Perspective
Drug | Quality of Evidence | Strength of Recommendation |
---|---|---|
Second-generation antihistamines (at licensed doses) | High | Strong (+) |
First-generation antihistamines | High | Strong (-) |
Second-generation antihistamines (at higher than licensed doses) | Moderate | Weak (+) |
Anti-H2-antihistamines as add-on therapy | Moderate | Weak (+) |
Oral corticosteroids (short course) | Low | Weak (+) |
Oral corticosteroids | Very low | Strong (-) |
Leukotriene receptor antagonists (as add-on therapy) | Low | Weak (+) |
Anti-inflammatory agents (dapsone, sulfasalazine, hydroxychloroquine, colchicines, mycophenolate mofetil) | Low-very low | Weak (+) |
Immunosuppressive agents | Â | Â |
   Cyclosporine | Moderate | Weak (+)* |
   Methotrexate | Very low | Weak (+) |
   Cyclophosphamide | Very low | Weak (+) |
Biologic agents | Â | Â |
   Omalizumab, | Moderate | Weak (+)* |
   IVIG | Low | Weak (+) |